European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
2016
Preuzimanje 🢃
Autori
Gossec, LaureSmolen, Josef S.
Ramiro, Sofia
Wit, Maarten de
Cutolo, Maurizio
Dougados, Maxime
Emery, Paul
Landewe, Robert
Oliver, Susan
Aletaha, Daniel
Betteridge, Neil
Braun, Juergen
Burmester, Gerd R.
Canete, Juan D.
Damjanov, Nemanja
FitzGerald, Oliver
Haglund, Emma
Helliwell, P.
Kvien, T. K.
Lories, Rik
Luger, Thomas
Maccarone, Mara
Marzo-Ortega, Helena
McGonagle, Dennis
McInnes, Iain B.
Olivieri, Ignazio
Pavelka, Karel
Schett, Georg
Sieper, Joachim
van den Bosch, F.
Veale, Douglas J.
Wollenhaupt, Juergen
Zink, Angela
van der Heijde, D.
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The over...arching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
Izvor:
Annals of the Rheumatic Diseases, 2016, 75, 3, 499-510Finansiranje / projekti:
- EULAR [CLI079]
DOI: 10.1136/annrheumdis-2015-208337
ISSN: 0003-4967; 1468-2060
PubMed: 26644232
WoS: 000371077700004
Scopus: 2-s2.0-84960126976
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Gossec, Laure AU - Smolen, Josef S. AU - Ramiro, Sofia AU - Wit, Maarten de AU - Cutolo, Maurizio AU - Dougados, Maxime AU - Emery, Paul AU - Landewe, Robert AU - Oliver, Susan AU - Aletaha, Daniel AU - Betteridge, Neil AU - Braun, Juergen AU - Burmester, Gerd R. AU - Canete, Juan D. AU - Damjanov, Nemanja AU - FitzGerald, Oliver AU - Haglund, Emma AU - Helliwell, P. AU - Kvien, T. K. AU - Lories, Rik AU - Luger, Thomas AU - Maccarone, Mara AU - Marzo-Ortega, Helena AU - McGonagle, Dennis AU - McInnes, Iain B. AU - Olivieri, Ignazio AU - Pavelka, Karel AU - Schett, Georg AU - Sieper, Joachim AU - van den Bosch, F. AU - Veale, Douglas J. AU - Wollenhaupt, Juergen AU - Zink, Angela AU - van der Heijde, D. PY - 2016 UR - https://vinar.vin.bg.ac.rs/handle/123456789/955 AB - Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. T2 - Annals of the Rheumatic Diseases T1 - European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update VL - 75 IS - 3 SP - 499 EP - 510 DO - 10.1136/annrheumdis-2015-208337 ER -
@article{ author = "Gossec, Laure and Smolen, Josef S. and Ramiro, Sofia and Wit, Maarten de and Cutolo, Maurizio and Dougados, Maxime and Emery, Paul and Landewe, Robert and Oliver, Susan and Aletaha, Daniel and Betteridge, Neil and Braun, Juergen and Burmester, Gerd R. and Canete, Juan D. and Damjanov, Nemanja and FitzGerald, Oliver and Haglund, Emma and Helliwell, P. and Kvien, T. K. and Lories, Rik and Luger, Thomas and Maccarone, Mara and Marzo-Ortega, Helena and McGonagle, Dennis and McInnes, Iain B. and Olivieri, Ignazio and Pavelka, Karel and Schett, Georg and Sieper, Joachim and van den Bosch, F. and Veale, Douglas J. and Wollenhaupt, Juergen and Zink, Angela and van der Heijde, D.", year = "2016", abstract = "Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.", journal = "Annals of the Rheumatic Diseases", title = "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update", volume = "75", number = "3", pages = "499-510", doi = "10.1136/annrheumdis-2015-208337" }
Gossec, L., Smolen, J. S., Ramiro, S., Wit, M. d., Cutolo, M., Dougados, M., Emery, P., Landewe, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G. R., Canete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., Lories, R., Luger, T., Maccarone, M., Marzo-Ortega, H., McGonagle, D., McInnes, I. B., Olivieri, I., Pavelka, K., Schett, G., Sieper, J., van den Bosch, F., Veale, D. J., Wollenhaupt, J., Zink, A.,& van der Heijde, D.. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases, 75(3), 499-510. https://doi.org/10.1136/annrheumdis-2015-208337
Gossec L, Smolen JS, Ramiro S, Wit MD, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester GR, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases. 2016;75(3):499-510. doi:10.1136/annrheumdis-2015-208337 .
Gossec, Laure, Smolen, Josef S., Ramiro, Sofia, Wit, Maarten de, Cutolo, Maurizio, Dougados, Maxime, Emery, Paul, Landewe, Robert, Oliver, Susan, Aletaha, Daniel, Betteridge, Neil, Braun, Juergen, Burmester, Gerd R. , Canete, Juan D. , Damjanov, Nemanja, FitzGerald, Oliver, Haglund, Emma, Helliwell, P., Kvien, T. K., Lories, Rik, Luger, Thomas, Maccarone, Mara, Marzo-Ortega, Helena, McGonagle, Dennis, McInnes, Iain B., Olivieri, Ignazio, Pavelka, Karel, Schett, Georg, Sieper, Joachim, van den Bosch, F., Veale, Douglas J., Wollenhaupt, Juergen , Zink, Angela, van der Heijde, D., "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update" in Annals of the Rheumatic Diseases, 75, no. 3 (2016):499-510, https://doi.org/10.1136/annrheumdis-2015-208337 . .